REVIEW  TAVI: NEW PERSPECTIVES 

Minerva Cardioangiologica 2019 February;67(1):57-63

DOI: 10.23736/S0026-4725.18.04794-1

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Degeneration of prosthesis after transcatheter aortic valve implantation

Giuliano COSTA, Corrado TAMBURINO, Marco BARBANTI ✉

Division of Cardiology, Vittorio Emanuele Polyclinic Hospital, University of Catania, Catania, Italy

With the expanding indication of transcatheter aortic valve implantation (TAVI) to younger, lower risk population, transcatheter aortic valve (TAV) long-term durability is becoming an emerging issue to face with. Recently, the standardization of structural valve deterioration (SVD) definition by a join committee of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) has permitted to evaluate for the first time the rates of TAV durability with comparable endpoint. A few studies reporting on structural valve dysfunction (SVD) after TAVI up to 8 years using these standardized criteria have found very low rates of valve deterioration, thus supporting the adoption of TAVI treatment even for younger patients. For patients showing SVD at follow-ups, the VIVID (Valve-in-Valve International Data) group recently proposed an algorithm for their management. Re-do TAVI seems to be a safer and valid alternative to re-do surgery for symptomatic patients. This article review will go through the current evidence of TAV durability, describing the types of failure and strategies of treatment.

KEY WORDS: Transcatheter aortic valve replacement - Heart valve prosthesis implantation - Prosthesis failure